Financial/nonfinancial disclosures: The authors have reported to CHEST the following: F. J. M. reports personal fees from Adept, Afferent, Amgen, AstraZeneca, Axon, Axon Communication, Boehringer Ingelheim, Clarion, ConCert, Forest, Genentech, GlaxoSmithKline, Ikaria/Bellerophon, Informa, Janssen, Kadmon, Lucid, Methodist Hospital, Novartis, Nycomed/Takeda, Pearl Therapeutics, Inc., Pfizer, Prime, Roche, Sunovion, Theravance, Unity Biotechnology, Veracyte, and WebMD. He has received nonfinancial support from Biogen/Stromedix, Boehringer Ingelheim, Centocor, and Gilead and grants from the National Institutes of Health. He has received personal fees for delivering CME programs for Academic CME, American Thoracic Society, Annenberg, California Society for Allergy and Immunology, CME Incite, Falco, Haymarket Communications, Integritas, InThought, Miller Medical, National Association for Continuing Education, Paradigm, Peer Voice, Potomac, UpToDate, and Western Society of Allergy and Immunology. He has received royalty fees from Informa and has spoken on behalf of AstraZeneca and Nycomed/Takeda. He is currently a member of the GOLD Scientific Committee. K. F. R. reports grants from Boehringer Ingelheim, the German Federal Ministry of Education and Research (BMBF), and Novartis. He has received personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Intermune, Novartis, and Takeda. G. T. F. reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Novartis, Pearl Therapeutics, Inc., Sunovian, and Theravance. He has received grants from Forest and personal fees from GlaxoSmithKline, Meda, Mylan, and Verona. L. M. F. reports grants, personal fees, and nonfinancial support from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Laboratori Guidotti, Merck Sharp & Dohme, Menarini, Novartis, and Takeda. He has received personal fees and nonfinancial support from Boston Scientific, Mundipharma, and Pearl Therapeutics, Inc. He has received personal fees from Bayer, Kyorin, and Zambon and has received grants from Biofutura Italia, Dompè, Malesci, Pfizer, and Vree Health Italia. S. R. reports grants from Almirall, AstraZeneca, Boehringer Ingelheim, Centocor, GlaxoSmithKline, NHLBI, Nebraska DHHS, Nycomed, Otsuka, and Pfizer. He has received personal fees from ABIM, Able Associates, Advantage Healthcare, Align2Action, Almirall, APT, ATS, AstraZeneca, Baxter, Boehringer Ingelheim, Chiesi, CIPLA, ClearView Healthcare, Cleveland Clinic, CME Incite, Complete Medical Group, COPDFoundation, Cory Paeth, CSA, CSL, CTS Carmel, Daiichi Sankyo, Decision Resources, Dunn Group, Easton Associates, Elevation Pharma, FirstWord, Forest, Frankel Group, Gerson, Gilead, GlaxoSmithKline, Grifols, GroupH, Guidepoint Global, Haymarket, HealthStar, Huron Consulting, Incite, Inthought, IntraMed (Forest), Johnson & Johnson, LEK, McKinsey, Medical Knowledge, MedImmune, Methodist Health System, Navigant, NCI Consulting, Novartis, Nuvis, Pearl Therapeutics, Inc., Penn Technology, Pfizer, PlanningShop, Prescott, Pro Ed Comm, ProiMed, PSL FirstWord, Pulmatrix, Quadrant, Qwessential, Regeneron, Saatchi and Saatchi, Schlesinger Associates, Strategic North, Synapse, Takeda, Theron, and WebMD. He is employed by AstraZeneca and also retains professorship and a part-time appointment at the University of Nebraska Medical Center. S. Sethi reports grants from AstraZeneca, Dey, and Pearl Therapeutics, Inc. He has received personal fees from AstraZeneca, Bayer, Boehringer Ingelheim, Cempra, CSL Behring, Forest, GlaxoSmithKline, Merck, Pearl Therapeutics, Inc., Pulmonx, Reckitt Benckiser, Sunovion, and Theravance. R. R-R. reports grants and personal fees from Almirall and Menarini. He has received personal fees from AstraZeneca, Boehringer Ingelheim, Ferrer, Mylan, Novartis, Pearl Therapeutics, Inc., Takeda, and TEVA. He is a member of the GOLD Board of Directors and of the Scientific Committee. T. M. S. reports grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Forest Research, Novartis, Oncocyte, Pearl Therapeutics, Inc., Proterix, Sunovian, and Theravance. He has received personal fees from AstraZeneca and Vapotherm. S. Siddiqui is an employee of AstraZeneca. P. D., T. F., A. M., M. G., C. O., and C. R. are employees of Pearl Therapeutics, Inc. None declared (G. J. F., S. Spangenthal, G. M. G., S. A.).